

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Directors**”) of The United Laboratories International Holdings Limited (the “**Company**”) is pleased to announce that Dr. Fu Qiushi (“**Dr. Fu**”) has been appointed as an independent non-executive Director of the Company and a member of the audit committee, the remuneration committee and the nomination committee of the Company, with effect from 30 June 2023.

The biographical details of Dr. Fu are set out below:

Dr. Fu, aged 51, has over 15 years of experience in investment management by acting as a partner of various venture capital institutions specialising in the investment in healthcare and biopharmaceutical industries. In July 2007, Dr. Fu started his venture capital career in Shenzhen Fortune Venture Capital Co. Ltd.* (深圳市達晨財智創業投資管理有限公司), mainly responsible for the investment in the healthcare industry. Dr. Fu is currently a partner of Shanghai Lichen Private Equity Management Co., Ltd.* (上海驪宸私募基金管理有限公司).

Dr. Fu obtained his bachelor degree in science from Peking University in 1994, a master degree in life sciences from Peking University in 1997, and a Doctor of Philosophy degree from the University of Illinois in 2004.

The Company has entered into a letter of appointment with Dr. Fu for an initial term of three years commencing from 30 June 2023, unless terminated by at least one month’s written notice served by either party at any time. Dr. Fu will hold office until the first general meeting of the Company after his appointment for re-election and will thereafter be subject to retirement by rotation and re-election in accordance with the provisions of the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Pursuant to the letter of appointment, Dr. Fu is entitled to an annual director fee of HK\$256,800, which is determined by the Board with reference to Dr. Fu’s qualification and experience, duties and responsibilities, and the Company’s remuneration policy.

Dr. Fu has confirmed that saved as disclosed in this announcement, as at the date of this announcement, he (i) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) has no other major appointments or professional qualifications; (iii) does not have any interest in the securities of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)); (iv) does not hold any other positions in the Company or its subsidiaries; and (v) does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (as defined under the Listing Rules). Saved as disclosed in this announcement, there are no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Dr. Fu or any other information that need to be disclosed pursuant to Rules 13.51(2)(b) to 13.51(2)(v) of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Dr. Fu in joining the Board.

COMPLIANCE WITH RULES 3.10(1), 3.10A AND 3.21 OF THE LISTING RULES

Reference is made to the announcement of the Company dated 31 March 2023 in relation to the resignation of an independent non-executive Director. Following the appointment of Dr. Fu as an independent non-executive Director, the Company has fully complied with Rules 3.10(1), 3.10A and 3.21 of the Listing Rules.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 30 June 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.

** For identification purposes only*